Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
Cancer attacks your body due to a random mutation of cells that gets out of control and spreads. The majority of breast cancers are hereditary, or blind unlucky chance. Fat is not directly linked with the enhanced cancer risk factor but it affects the estrogen hormone balance in your body which play....
It’s very much unlikely. If the opposite armpit develops swollen nodes, it could be anything from an ingrown hair to a skin disease, to a swollen lymph node caused by an infection or even an injury down your arm. Many of these conditions require further testing or treatment. It is important to see y....
Understanding the difference between chemotherapy and radiation treatment can help you be more prepared for visits to your doctor. Various treatment options are available for patients suffering from cancer. Based on the type and stage of cancer, when the patient is diagnosed, patient’s overall he....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
كُتب بواسطة:Dr. Nitika Sharma - BDS
تمت مراجعته من قبل:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.